Oxford University Press eBooks,
Journal Year:
2025,
Volume and Issue:
unknown, P. 652 - 684
Published: Jan. 30, 2025
Abstract
Truck
drivers
have
a
high
prevalence
of
depression.
Their
life
expectancies
are
short,
in
part
due
to
unhealthy
lifestyles
and
associated
chronic
diseases.
Depressed
more
likely
be
involved
crashes.
occupational
risk
factors
for
injury,
general
medical
illness,
depression
include
chronobiologic
stress;
continual
exposure
noise,
vibration,
polluted
air;
poor-quality
food
at
truck
stops;
prolonged
periods
sitting;
time
pressures;
loneliness
when
away
from
home;
work–family
conflicts;
work
schedules
that
interfere
with
consistent
healthcare.
Obesity
sleep
apnea
prevalent
challenging
treat.
Drivers’
culture
contributes
normalization
illness
pain,
denial
or
externalization
depression,
internal
stigma.
Evaluation
depressed
driver
should
identify
addressable
job-related
neglected
problems.
Enhancement
function
crash
prevention
non-stigmatizing
foci
clinical
intervention
compatible
culture.
Metabolites,
Journal Year:
2025,
Volume and Issue:
15(2), P. 124 - 124
Published: Feb. 13, 2025
Neurodegenerative
diseases
comprise
a
group
of
chronic,
usually
age-related,
disorders
characterized
by
progressive
neuronal
loss,
deformation
structure,
or
loss
function,
leading
to
substantially
reduced
quality
life.
They
remain
significant
focus
scientific
and
clinical
interest
due
their
increasing
medical
social
importance.
Most
neurodegenerative
present
intracellular
protein
aggregation
extracellular
deposition
(plaques),
such
as
α-synuclein
in
Parkinson's
disease
amyloid
beta
(Aβ)/tau
aggregates
Alzheimer's.
Conventional
treatments
for
conditions
incur
high
costs
are
related
the
development
several
adverse
effects.
In
addition,
many
patients
irresponsive
them.
For
these
reasons,
there
is
growing
tendency
find
new
therapeutic
approaches
help
patients.
This
review
intends
investigate
some
phytocompounds'
effects
on
diseases.
These
generally
increased
oxidative
stress
inflammation,
so
phytocompounds
can
prevent
treat
To
achieve
our
aim
provide
critical
assessment
current
literature
about
phytochemicals
targeting
neurodegeneration,
we
reviewed
reputable
databases,
including
PubMed,
EMBASE,
COCHRANE,
seeking
trials
that
utilized
against
conditions.
A
few
investigated
humans,
after
screening,
13
were
ultimately
included
following
PRISMA
guidelines.
compounds
include
polyphenols
(flavonoids
luteolin
quercetin,
phenolic
acids
rosmarinic
acid,
ferulic
caffeic
other
like
resveratrol),
alkaloids
(such
berberine,
huperzine
A,
caffeine),
terpenoids
ginkgolides
limonene).
The
gathered
evidence
underscores
caffeine,
ginkgolides,
primarily
anti-inflammatory,
antioxidant,
neuroprotective,
counteracting
neuroinflammation,
oxidation,
synaptic
dysfunctions,
which
crucial
aspects
intervention
various
conditions,
Alzheimer's
dementias,
depression,
neuropsychiatric
disorders.
summary,
they
show
use
improvements
cognition,
memory,
disinhibition,
irritability/lability,
aberrant
behavior,
hallucinations,
mood
Pharmacological Research,
Journal Year:
2024,
Volume and Issue:
207, P. 107322 - 107322
Published: July 20, 2024
Depression
is
a
common
mental
disorder,
the
effective
treatment
of
which
remains
challenging
issue
worldwide.
The
clinical
pathogenesis
depression
has
been
deeply
explored,
leading
to
formulation
various
pathogenic
hypotheses.
Among
these,
monoamine
neurotransmitter
hypothesis
holds
prominent
position,
yet
it
significant
limitations
as
more
than
one-third
patients
do
not
respond
conventional
treatments
targeting
transmission
disturbances.
Over
past
few
decades,
growing
body
research
highlighted
link
between
inflammation
and
potential
key
factor
in
pathophysiology
depression.
In
this
review,
we
first
summarize
relationship
depression,
with
focus
on
pathophysiological
changes
mediated
by
mechanisms
linking
well
multiple
anti-inflammatory
strategies
are
also
discussed,
their
efficacy
safety
assessed.
This
review
broadens
perspective
specific
aspects
using
for
treating
laying
groundwork
advancing
precision
medicine
individuals
suffering
from
"inflamed"
Brain Sciences,
Journal Year:
2024,
Volume and Issue:
14(6), P. 558 - 558
Published: May 30, 2024
Mood
disorders
and
substance
use
disorder
(SUD)
are
of
immense
medical
social
concern.
Although
significant
progress
on
neuronal
involvement
in
mood
reward
circuitries
has
been
achieved,
it
is
only
relatively
recently
that
the
role
glia
these
attracted
attention.
Detailed
understanding
glial
functions
devastating
diseases
could
offer
novel
interventions.
Here,
following
a
brief
review
involved
regulation
perception,
specific
contributions
neurotrophic
factors,
neuroinflammation,
gut
microbiota
to
highlighted.
In
this
context,
cells
(e.g.,
microglia,
astroglia,
oligodendrocytes,
synantocytes)
phenotypic
manifestation
or
SUD
emphasized.
addition,
knowledge
potential
development
therapeutics
touched
upon.
Pharmaceuticals,
Journal Year:
2025,
Volume and Issue:
18(1), P. 104 - 104
Published: Jan. 15, 2025
Cytokine-mediated
inflammation
is
increasingly
recognized
for
playing
a
vital
role
in
the
pathophysiology
of
wide
range
brain
disorders,
including
neurodegenerative,
psychiatric,
and
neurodevelopmental
problems.
Pro-inflammatory
cytokines
such
as
interleukin-1
(IL-1),
tumor
necrosis
factor-alpha
(TNF-α),
interleukin-6
(IL-6)
cause
neuroinflammation,
alter
function,
accelerate
disease
development.
Despite
progress
understanding
these
pathways,
effective
medicines
targeting
are
still
limited.
Traditional
anti-inflammatory
immunomodulatory
drugs
peripheral
inflammatory
illnesses.
Still,
they
face
substantial
hurdles
when
applied
to
central
nervous
system
(CNS),
blood-brain
barrier
(BBB)
unwanted
systemic
effects.
This
review
highlights
developing
treatment
techniques
modifying
cytokine-driven
focusing
on
advances
that
selectively
target
critical
involved
pathology.
Novel
approaches,
cytokine-specific
inhibitors,
antibody-based
therapeutics,
gene-
RNA-based
interventions,
sophisticated
drug
delivery
systems
like
nanoparticles,
show
promise
with
respect
lowering
neuroinflammation
greater
specificity
safety.
Furthermore,
developments
biomarker
discoveries
neuroimaging
improving
our
ability
monitor
responses,
allowing
more
accurate
personalized
regimens.
Preclinical
clinical
trial
data
demonstrate
therapeutic
potential
tailored
techniques.
However,
significant
challenges
remain,
across
BBB
reducing
off-target
As
research
advances,
creation
personalized,
cytokine-centered
therapeutics
has
therapy
landscape
illnesses,
giving
patients
hope
better
results
higher
quality
life.
Frontiers in Neuroscience,
Journal Year:
2025,
Volume and Issue:
19
Published: Feb. 6, 2025
The
hypothalamus-pituitary-adrenal
(HPA)
and
gut-brain
axes
are
vital
biological
pathways
in
depression.
HPA
axis
regulates
the
body's
stress
response,
chronic
can
lead
to
overactivation
of
axis,
resulting
elevated
cortisol
levels
that
contribute
neuronal
damage,
particularly
regions
such
as
hippocampus
prefrontal
cortex,
both
which
involved
mood
regulation
mental
disorders.
In
parallel,
a
bidirectional
communication
network
between
gut
microbiota
central
nervous
system,
influences
emotional
cognitive
functions.
Imbalances
affect
promoting
inflammation
increasing
permeability.
This
allows
endotoxins
enter
bloodstream,
contributing
neuroinflammation
altering
neurotransmitter
production,
including
serotonin.
Since
majority
serotonin
is
produced
gut,
disruptions
this
pathway
may
be
linked
depressive
symptoms.
review
explores
interplay
context
Frontiers in Cellular Neuroscience,
Journal Year:
2024,
Volume and Issue:
18
Published: Nov. 22, 2024
Major
depressive
disorder
is
a
complex
and
multifactorial
condition,
increasingly
linked
to
neuroinflammation
astrocytic
dysfunction.
Astrocytes,
along
with
other
glial
cells,
beyond
their
classic
functions
in
maintaining
brain
homeostasis,
play
crucial
role
regulating
neuroplasticity,
key
processes
the
pathophysiology
of
depression.
This
mini-review
explores
involvement
astrocytes
depression
emphasizing
mediation
processes,
impact
dysfunction
on
effect
some
antidepressants
astrocyte
reactivity.
Recent
evidence
suggests
that
targeting
astrocyte-related
signaling
pathways,
particularly
balance
between
different
phenotypes,
could
offer
promising
for
therapeutic
strategies
affective
disorders.
Therefore,
deeper
understanding
biology
may
open
way
innovative
treatments
aimed
at
mitigating
symptoms
by
impacting
both
imbalances
neuroplasticity.
Designed Monomers & Polymers,
Journal Year:
2024,
Volume and Issue:
28(1), P. 1 - 34
Published: Dec. 31, 2024
This
review
paper
analyzes
recent
advancements
in
bio-polymer
coatings
for
probiotic
microencapsulation,
with
a
particular
emphasis
on
chitosan
and
its
synergistic
combinations
other
materials.
Probiotic
microencapsulation
is
essential
protecting
probiotics
from
environmental
stresses,
enhancing
their
stability,
ensuring
effective
delivery
to
the
gut.
The
begins
an
overview
of
highlighting
significance
safeguarding
through
processing,
storage,
gastrointestinal
transit.
Advances
chitosan-based
encapsulation
are
explored,
including
integration
bio-polymers
such
as
alginate,
gelatin,
pectin,
well
application
nanotechnology
innovative
techniques
like
spray
drying
layer-by-layer
assembly.
Detailed
mechanistic
insights
integrated,
illustrating
how
influences
gut
microbiota
by
promoting
beneficial
bacteria
suppressing
pathogens,
thus
role
prebiotic
or
synbiotic.
Furthermore,
delves
into
chitosan's
immunomodulatory
effects,
particularly
context
inflammatory
bowel
disease
(IBD)
autoimmune
diseases,
describing
immune
signaling
pathways
influenced
linking
changes
improvements
systemic
immunity.
Recent
clinical
trials
human
studies
assessing
efficacy
chitosan-coated
presented,
alongside
discussion
practical
applications
comparison
vitro
vivo
findings
highlight
real-world
relevance.
sustainability
sources
impact
addressed,
along
novel
concept
gut-brain
axis.
Finally,
emphasizes
future
research
needs,
development
personalized
therapies
exploration
techniques.
